Wednesday 4 November 2026 Export ENTX’s income statement to Excel — free account

Entera Bio Ltd.

ENTX Healthcare Biotechnology

Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024.

Revenue: +200.0%
EPS: −133.3%
Free cash flow: −108.9%

Quarter to June 2026, against a year earlier

Insider buying

3.14 0.09 +2.95%

Follow ENTX

Alert me

Market cap: $530.5M
P/E: 0.0×
Fwd P/E: −8.0×
Dividend yield: —
F-score: n/a
Altman Z: 6.22
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.14

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	1	—	5	2	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 530.46

Revenue ttm 0.22

Net income ttm (17.03)

Free cash flow ttm (10.99)

Net debt Q (18.43)

Valuation

P/E 0.00

Forward P/E (7.96)

Price / sales 694.55

Forward P/S Powerpack

Price / FCF 0.00

Price / book 21.32

Financial health

Current ratio Q 8.98

Debt / equity Q 0.00

Interest coverage Q (66.28)

Growth

Revenue growth Q +200.00%

Operating income growth Q −71.03%

EPS, this year −67.00%

EPS, next year A +8.38%

Revenue, next year A 0.00%

EPS, past 5 yrs —

EPS, next 5 yrs A −17.20%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 98.84%

10-year low 10-year high

P/B against its own 10 years 99.34%

10-year low 10-year high

EV/Sales against its own 10 years 97.85%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11	9	15	18
Receivables	—	0	—	—
Inventory	—	—	—	—
Other	0	0	0	0
	11	9	15	19

	2023	2024	2025	Q'26
Payables	0	0	0	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	1	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	(29.19%)	(58.10%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	11.77%	3.68%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.08 Actual −0.14

−0.15 −0.13 −0.11 −0.08 −0.06

Q3 FY25 Beat +0.02

Q4 FY25 Beat +0.02

Q1 FY26 Beat +0.01

Q2 FY26 Miss −0.06

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.09	−0.07	Beat by 0.02
Q4 FY25	−0.09	−0.07	Beat by 0.02
Q1 FY26	−0.08	−0.07	Beat by 0.01
Q2 FY26	−0.08	−0.14	Miss by 0.06

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.07)	(0.14)	—	—	—
’25	(0.06)	(0.06)	(0.07)	(0.07)	(0.25)
’24	(0.05)	(0.06)	(0.08)	(0.06)	(0.25)
’23	(0.08)	(0.08)	(0.08)	(0.07)	(0.31)
’22	(0.13)	(0.11)	(0.11)	(0.10)	(0.45)
’21	(0.10)	(0.10)	(0.11)	(0.15)	(0.47)
’20	(0.16)	(0.17)	(0.09)	(0.18)	(0.55)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	—	—	—	0
’24	—	0	0	0	0
’22	0	0	0	0	0
’21	0	0	0	0	1
’20	0	0	0	0	0
’19	—	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(1)	(2)	(3)	(2)	(7)
’24	(2)	(1)	(2)	(1)	(7)
’23	(2)	(2)	(2)	(3)	(7)
’22	(5)	(3)	(3)	(2)	(12)
’21	(2)	(2)	(2)	(3)	(9)
’20	(3)	(4)	(3)	(2)	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(1)	(2)	(3)	(2)	(7)
’24	(2)	(1)	(2)	(1)	(7)
’23	(2)	(2)	(2)	(3)	(7)
’22	(5)	(3)	(3)	(2)	(13)
’21	(2)	(2)	(2)	(3)	(9)
’20	(3)	(4)	(3)	(2)	(11)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	1	0	0	1	0	—	0	0	0		(29.8%)	0	—	—	0.0%
	Gross margin, %	0.00	0.00	100.00	11.02	17.81	34.68	24.63	—	4.97	0.00	0.00		0.0 pt	Powerpack Entera Bio Ltd.’s next three years, line by line Analysts expect revenue to grow 0.0% a year to 2028 — faster than the −29.8% of the last 7 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(1)	(11)	(10)	(11)	(11)	(12)	(13)	(9)	(10)	(11)	(17)		+28.5%
	EBT margin, %	0.00	0.00	(2,060.80)	(4,574.15)	(3,067.40)	(2,144.66)	(9,652.24)	0.00	(5,263.54)	(27,235.71)	0.00		(27,235.7) pt
	Net income	(1)	(11)	(10)	(11)	(11)	(12)	(13)	(9)	(10)	(11)	(17)		+28.5%
Per share, $
Per share, $	Revenue	0.00	0.00	0.06	0.02	0.02	0.02	0.00	0.00	0.00	0.00	0.00		n/m
	Earnings	(0.10)	(2.49)	(1.30)	(0.89)	(0.61)	(0.47)	(0.45)	(0.31)	(0.25)	(0.25)	(0.35)		+10.7%
	Cash flow	(0.27)	(1.01)	(1.23)	(0.73)	(0.57)	(0.35)	(0.43)	(0.25)	(0.18)	(0.16)	(0.22)		(5.7%)
	Capex	0.00	(0.01)	(0.01)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Free cash flow	(0.27)	(1.02)	(1.24)	(0.74)	(0.58)	(0.35)	(0.44)	(0.25)	(0.18)	(0.16)	(0.22)		(5.5%)
	Book value	(2.17)	(7.03)	1.27	0.98	0.41	0.86	0.41	0.36	0.21	0.28	0.14		n/m
	Shares, m	12	4	8	12	18	26	29	29	38	46	48		+16.6%
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	—	0.00	0.00	0.00		0.0
	P/S	—	—	0.00	35.32	54.49	129.07	219.28	—	409.32	401.84	694.55		178.5
	P/B	—	—	4.73	2.18	2.65	3.27	2.50	—	9.88	6.84	21.32		4.6
	EV/Sales	—	—	0.00	19.98	41.62	92.29	156.48	—	384.88	352.56	629.36		149.7
	EV/FCF	—	—	(4.08)	(1.64)	(1.43)	(5.79)	(1.67)	—	(10.99)	(10.51)	(12.77)		(5.2)
Cash, $m
Cash, $m	Operating cash flow	(3)	(5)	(10)	(9)	(11)	(9)	(12)	(7)	(7)	(7)	(11)		+9.9%
	Capex	—	0	0	0	0	0	0	0	0	0	0		+9.7%
	Free cash flow	(3)	(5)	(10)	(9)	(11)	(9)	(13)	(7)	(7)	(7)	(11)		+10.1%
Balance, $m
Balance, $m	Working capital	(5)	10	9	11	7	22	12	10	8	13	17		n/m
	Net debt	21	(8)	(12)	(15)	(9)	(25)	(12)	(11)	(9)	(15)	(18)		n/m
	Shareholders’ equity	(25)	(32)	10	12	8	23	12	10	8	13	7		n/m
Returns, %
Returns, %	ROA	(12.26)	(114.47)	(77.42)	(71.86)	(84.89)	(68.26)	(66.84)	(71.42)	(90.20)	(90.13)	(87.02)		(77.9) pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	ROE	4.22	39.42	96.11	(97.98)	(115.46)	(81.04)	(76.17)	(80.30)	(103.34)	(108.01)	(138.92)		(112.2) pt
People
People	Employees	—	19	19	26	18	27	20	19	20	22	—		+1.8%
	Revenue/emp, $m	—	0.00	0.03	0.01	0.02	0.02	0.01	0.00	0.01	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BCAX Bicara Therapeutics Inc.	$592.9M	— (loss-making)	—	—	n/m	−72.95% (below 0%: shrinking)	—	0.00%	Compare
ANL Adlai Nortye Ltd. Sponsored ADR	$562.6M	—	—	—	—	+46.03% (above 0%: growing)	—	—	Compare
ACRS Aclaris Therapeutics, Inc.	$550.5M	— (loss-making)	— (loss-making)	−8.33% (below 0%: shrinking)	n/m	−98.77% (below 0%: shrinking)	10.80%	(1,487.91%)	Compare
STTK Shattuck Labs, Inc.	$549.0M	— (loss-making)	— (loss-making)	−10.31% (below 0%: shrinking)	n/m	+1.01% (above 0%: growing)	100.00%	0.00%	Compare
NGNE Neurogene Inc.	$533.7M	— (loss-making)	— (loss-making)	—	n/m	−22.97% (below 0%: shrinking)	100.00%	0.00%	Compare
ENTX Entera Bio Ltd.	$530.5M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	−108.86% (below 0%: shrinking)	0.00%	0.00%
PBYI Puma Biotechnology, Inc.	$527.6M	18.9×	24.2×	+7.75% (above 0%: growing)	+33.33% (above 0%: growing)	−88.45% (below 0%: shrinking)	77.92%	13.42%	Compare
CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR	$524.8M	— (loss-making)	— (loss-making)	−7.53% (below 0%: shrinking)	n/m	−31.52% (below 0%: shrinking)	0.00%	0.00%	Compare
INDP Indaptus Therapeutics, Inc.	$497.6M	— (loss-making)	—	—	n/m	+52.03% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$541.3M	—	—	−7.93%	—	−27.24%	44.36%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 14 October 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	1.48m	1.35m	223.00
2024	1.15m	2.19m	212.00

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Entera Bio Ltd. (ENTX) Latest News

27 Oct

Impact 4 · 8:00 AM · GlobeNewswire

Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors

19 Oct

Impact 3 · 4:05 PM · PR Newswire

Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

13 Oct

Impact 4 · 7:00 AM · GlobeNewswire

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting

6 Oct

Impact 4 · 8:00 AM · GlobeNewswire

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

18 Aug

Impact 4 · 8:00 AM

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

13 Aug

Impact 4 · 2:04 PM · MarketBeat

Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement

7 Aug

Impact 3 · 4:05 PM

Entera Announces Second Quarter 2026 Financial Results and Business Updates

4 Aug

Impact 3 · 8:30 AM

Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting

27 Jul

Impact 4 · 8:30 AM

Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement

22 Jun

Impact 4 · 8:30 AM · GlobeNewswire

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Impact 3 · 2:29 PM · Stocktwits

ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?

16 Jun

Impact 3 · 8:33 AM

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

15 Jun

Impact 4 · 8:45 AM

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

28 May

Impact 3 · 8:50 AM · GlobeNewswire

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

8 May

Impact 4 · 4:05 PM · GlobeNewswire

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

29 Apr

Impact 3 · 12:00 PM · Zacks

Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know

24 Apr

Impact 4 · 7:33 PM · MarketBeat

Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near

20 Apr

Impact 3 · 11:59 AM

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

2 Apr

Impact 4 · 8:45 AM · GlobeNewswire

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

27 Mar

Impact 3 · 4:05 PM · GlobeNewswire

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

4 Mar

Impact 4 · 8:30 AM · GlobeNewswire

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

11 Feb

Impact 3 · 9:00 AM · GlobeNewswire

Entera Bio Announces Open Market Purchases of Company Stock by Board Members

9 Feb

Impact 4 · 8:50 AM · GlobeNewswire

Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones

6 Feb

Impact 4 · 11:02 AM · Insider Monkey

Opko Health (OPK) Expands Entera Partnership for Drug Co-Development

4 Feb

Impact 4 · 8:00 AM · GlobeNewswire

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

Impact 4 · 8:00 AM

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

21 Jan

Impact 4 · 8:30 AM · GlobeNewswire

Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook

31 Dec

Impact 3 · 7:51 AM · Simply Wall St.

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

23 Dec

Impact 4 · 8:30 AM · GlobeNewswire

Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

22 Dec

Impact 4 · 8:30 AM

Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Entera Bio Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 14 October 2026

Chief executive’s pay

Entera Bio Ltd. (ENTX) Latest News

27 Oct

19 Oct

13 Oct

6 Oct

18 Aug

13 Aug

7 Aug

4 Aug

27 Jul

22 Jun

16 Jun

15 Jun

28 May

8 May

29 Apr

24 Apr

20 Apr

2 Apr

27 Mar

4 Mar

11 Feb

9 Feb

6 Feb

4 Feb

21 Jan

31 Dec

23 Dec

22 Dec

Stockrow Weekly